Menopause hormone therapy: what the modern evidence really shows

What the science says

If you trained in the shadow of the early Women’s Health Initiative (WHI) headlines, you probably absorbed a simple message: hormone therapy is risky and should be avoided whenever possible. Two decades and a large body of follow-up data later, that story is more complicated—and considerably more reassuring for many women.

Broadly, the modern evidence supports several key points:

• Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms (hot flashes, night sweats) and genitourinary syndrome of menopause (vaginal dryness, dyspareunia, recurrent urinary symptoms).[15]
• For healthy women younger than 60 or within 10 years of their final menstrual period, the absolute risks of MHT are low, and benefits usually outweigh harms when symptoms are bothersome.[14]
• Route, dose, and regimen matter. Lower-dose and transdermal estrogen, paired with body-identical (micronized) progesterone when needed, appear to carry a different risk profile than the oral conjugated equine estrogen plus medroxyprogesterone acetate used in the original WHI trial.[14][12]
• The risk–benefit balance shifts with age and time since menopause. Starting systemic MHT after age 60 or more than 10 years post-menopause is consistently associated with higher cardiovascular and thrombotic risk.[11][14]
• Across outcomes—from fractures to diabetes, cardiovascular disease, and several cancers—the picture is mixed rather than uniformly good or bad, with risk patterns varying by estrogen-only vs combined therapy, treatment duration, and underlying health.[12]

A large umbrella review of systematic reviews and meta-analyses concluded that MHT has a “complex balance of benefits and harms”, with moderate-to-poor quality of evidence across many endpoints, despite decades of research.[12] In parallel, contemporary narrative reviews and guidelines from specialty societies converge on a more pragmatic message: for appropriately selected women, modern MHT is both reasonable and often underused.[14][15][3]

How it works

Menopause reflects a progressive decline in ovarian estrogen and progesterone production, leading to thermoregulatory instability, urogenital atrophy, sleep disruption, and shifts in lipid and glucose metabolism.[14][15] MHT attempts to partially replace these hormones, not to recreate premenopausal physiology, but to reduce symptom burden and modulate long-term health risks.

Estrogen: central player

Estrogen therapy is the cornerstone of MHT. It:

• Stabilizes hypothalamic thermoregulatory centers, reducing hot flashes and night sweats.[14][15]
• Improves urogenital blood flow and epithelial integrity, easing vaginal dryness and dyspareunia and lowering recurrent urinary tract symptoms.[15]
• Favorably alters lipid profiles (lower LDL, higher HDL), though effects on actual cardiovascular events are highly context-dependent.[14]
• Reduces bone resorption and lowers fracture risk while on therapy.[12]

In women with a uterus, unopposed estrogen promotes endometrial proliferation and increases risk of hyperplasia and cancer. This is why progestogens are added for endometrial protection.

Progestogens: endometrial protection, differential risks

Progestogens (progestins and micronized progesterone) counteract estrogen-driven endometrial growth, reducing the risk of endometrial cancer to baseline or below when used adequately.[14]

However, breast and vascular risks appear to vary across progestogen types:

• WHI’s increased breast cancer risk signal was largely observed with conjugated equine estrogen (CEE) plus medroxyprogesterone acetate, not with estrogen alone.[14][12]
• Observational data suggest that estradiol plus micronized progesterone may be associated with a lower breast cancer risk than some synthetic progestins, though residual confounding cannot be excluded.[9]

Route and dose: why transdermal matters

The route of administration shapes hepatic first-pass effects:

• Oral estrogen increases hepatic synthesis of clotting factors, C-reactive protein, and triglycerides, all of which may contribute to increased risk of venous thromboembolism (VTE) and stroke in susceptible women.[11][14]
• Transdermal estrogen (patches, gels, sprays) bypasses the liver’s first pass and is associated with lower VTE and possibly stroke risk, especially at standard doses.[14]

Modern practice has moved toward lower doses and transdermal routes, particularly in women with higher baseline cardiometabolic risk.[4][14]

Timing: the “window of opportunity” hypothesis

Cardiovascular effects seem to depend heavily on when MHT is started:

• Initiation within 10 years of menopause or before age 60 appears associated with neutral or favorable cardiovascular outcomes in relatively healthy women.[14][4]
• Initiation later in life or well after menopause is more often linked to increased risks of coronary events, stroke, and VTE.[11][4]

This “timing hypothesis” proposes that estrogen is more likely to be beneficial in a relatively healthy endothelium early after menopause, but may be harmful in advanced atherosclerotic disease.[4]

What the evidence supports

Symptom relief and quality of life

The evidence is strongest here:

• Systemic MHT reduces hot flashes by ~75% and improves sleep, mood, and overall quality of life in symptomatic women.[15][14]
• Low-dose local vaginal estrogen, with minimal systemic absorption, is highly effective for genitourinary syndrome of menopause and is considered safe for most women, including many who are not candidates for systemic therapy.[15]

Bone health and fractures

• Multiple trials and systematic reviews confirm that MHT increases bone mineral density and reduces vertebral and non-vertebral fractures while therapy is continued.[12]
• Once treatment stops, fracture protection declines over time, so MHT is not typically used as a first-line, lifelong osteoporosis therapy; it is one option among others, particularly for symptomatic younger women in early menopause.[11][12]

Cardiovascular disease and metabolic outcomes

The signal is nuanced:

• In the WHI estrogen-only arm (women with hysterectomy), CEE was associated with reduced coronary heart disease and all-cause mortality in women aged 50–59 at randomization, particularly on extended follow-up.[14]
• For combined CEE plus medroxyprogesterone, early WHI results showed increased risks of coronary events and stroke overall, but age-stratified and long-term analyses suggest that absolute risks are small in younger, recently menopausal women and higher with advancing age and time since menopause.[14]
• MHT improves insulin sensitivity and lipid profiles, and may lower risk of type 2 diabetes while on therapy, though not enough to justify use solely for metabolic prevention.[12]
• Transdermal regimens appear more cardiometabolically neutral and are increasingly preferred in women with obesity, metabolic syndrome, or elevated VTE risk.[4][14]

Breast cancer

This remains the lightning rod, but the picture is more differentiated than early headlines suggested:

• In WHI, estrogen-only therapy (CEE) was associated with a reduced incidence and mortality from breast cancer versus placebo over long-term follow-up.[14][12]
• Combined estrogen–progestin therapy was associated with a modestly increased risk of breast cancer, which rose with longer duration and declined after discontinuation.[12]
• Observational data indicate that risk varies by progestogen type, with estradiol plus micronized progesterone linked to lower or neutral risk compared with some synthetic progestins, though causality is not definitively established.[9][6]
• In absolute terms, the excess breast cancer risk from several years of combined MHT in a woman in her 50s appears smaller than the risk conferred by obesity or heavy alcohol use.[9]

Cognitive function and dementia

• Starting standard-dose MHT after age 65 has been associated with increased dementia risk in some trials, notably with CEE plus medroxyprogesterone.[12]
• Evidence is insufficient to recommend MHT for cognitive protection, and major societies currently discourage its use solely for dementia prevention.[11][14]

Women with complex or high-risk profiles

Guidelines and real-world data are evolving for women with cancer histories, thrombophilia, or multimorbidity:

• In women with or at high risk for breast or ovarian cancer, decisions around MHT are highly individualized. Some data suggest that carefully selected survivors may use MHT without major adverse impact on survival, but uncertainty persists and shared decision-making with oncology is essential.[6]
• A narrative review of clinically vulnerable women underscores that evidence is sparse for those with advanced age, significant multimorbidity, or prior thromboembolic events, and that many guidelines rely on expert consensus rather than robust trial data in these groups.[3]

Practical takeaways

For clinicians and informed patients, modern data support a more personalized, risk-stratified approach rather than blanket avoidance.

Who is most likely to benefit

Women who are:

• Under 60 years old or within 10 years of menopause, and
• Experiencing moderate-to-severe vasomotor or sleep-disrupting symptoms, or
• Have premature ovarian insufficiency or early menopause (where replacing estrogen until the natural age of menopause reduces cardiovascular and bone risks)[11][15]

are the group in whom benefits generally outweigh risks when no major contraindications exist.[14]

How to think about regimen choice

A pragmatic framework emerging from current reviews and guidelines:[11][14][15]

• Route

  • Prefer transdermal estradiol in women with elevated cardiometabolic or VTE risk, migraine, or significant obesity.
  • Oral options may be reasonable for healthy, low-risk women who prefer them.

• Progestogen (for women with a uterus)

  • Favor micronized progesterone or certain dydrogesterone-based regimens when available, given more favorable or neutral breast and vascular signals in observational data.[9][14]

• Dose and duration

  • Start with the lowest effective dose for symptom control.
  • Reassess yearly; many guidelines consider up to 5 years of combined therapy reasonable for symptom relief, with individualized decisions beyond that.[11][14]

• Local vs systemic

  • Use local vaginal estrogen (or DHEA, or selective estrogen receptor modulators) for predominantly genitourinary symptoms, especially in women who are not candidates for systemic therapy.[15]

Non-hormonal options still matter

For women who cannot or do not want systemic MHT, or who need adjunctive measures:

• SSRIs/SNRIs, gabapentin, and newer neurokinin-3 receptor antagonists can reduce vasomotor symptoms.[15]
• Lifestyle interventions—cooling strategies, weight management, alcohol moderation, exercise, and sleep hygiene—offer modest relief and broader health benefits, even if they do not match MHT’s efficacy for hot flashes.[15]

Caveats and unknowns

Despite the volume of data, much of the modern MHT conversation is still built on heterogeneous trials and observational studies with important limitations.

• The umbrella review of MHT and women’s health graded much of the evidence as moderate or low quality, citing inconsistency, publication bias, and residual confounding.[12]
• WHI used specific formulations (CEE ± medroxyprogesterone) at fixed doses that do not neatly map onto today’s lower-dose transdermal estradiol plus micronized progesterone regimens.[14]
• Long-term safety data for newer preparations and routes (e.g., ultra-low-dose patches, combination products, and body-identical regimens) are still comparatively limited.
• Women with multimorbidity, advanced age, or diverse racial and ethnic backgrounds remain underrepresented in clinical trials, limiting the external validity of traditional recommendations.[3][4]
• Data on very long-term use (beyond 10–15 years) of modern regimens are sparse; most guidance relies on extrapolation and expert consensus rather than randomized trial evidence.

For now, the most defensible position is neither pro-hormone nor anti-hormone, but pro-clarity: explaining that for many symptomatic women in early menopause, modern MHT—with careful choice of dose, route, and regimen—offers meaningful quality-of-life gains with relatively small absolute risks. The task is less about selling therapy and more about restoring nuance to a conversation that was, for a time, reduced to headlines.